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Genetically engineered mouse modelThe metalloproteinase family includes MMP, ADAM and ADAMTS proteases. Mice deﬁcient in individual or
pairs of metalloproteinases have been generated, and a number of these genetic models spontaneously
develop skeletal abnormalities. Here we review metalloproteinase function in endochondral and
intramembranous ossiﬁcation, as well as in postnatal bone remodeling. We highlight howmetalloproteinases
enable interactions between distinct bone cell types and how this communication contributes to the skeletal
phenotypes observed in knockout mice. In addition to the physiological actions of metalloproteinases in the
skeletal system, the experimental manipulation of metalloproteinase-deﬁcient mice has revealed substantial
roles for these enzymes in osteoarthritis and rheumatoid arthritis. MMP, ADAM and ADAMTS proteases thus
emerge as key players in the development and homeostasis of the skeletal system.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
The extracellular matrix (ECM) is a highly heterogeneous mix of
collagens, other proteins and proteoglycans that is essential for
shaping multi-cellular organisms and imparting key characteristics to
tissues. In vertebrates, the calciﬁed bone matrix provides the
structural plan for the body, protects organs, anchors themusculature,
houses the bone marrow and acts as a calcium reservoir. Bone is a
dynamic organ primarily composed of three cell types. At the bone
surface are osteoclasts which degrade bone as well as osteoblasts
which deposit new bone matrix and play a role in its mineralization.
As bone is being formed, some osteoblasts become encased in their
ECM and transition into osteocytes. These cells are the mechano-
sensors of bone and have unique structures and functions that will be
described further in this review. Cartilage, the second major
component of the skeleton, is avascular, rich in proteoglycans and
type II collagen, and is constituted by chondrocytes. The extracellular
matrix of growth plate cartilage is synthesized and maintained by
chondrocytes of progressive maturity and contributes to the longitu-
dinal growth of bone. Articular cartilage at joint surfaces has a
different structure from that of growth plate cartilage and contributes
to both efﬁcient weight-bearing and the reduction of friction during
joint movement.
Metalloproteinases, whichwere ﬁrst identiﬁed as collagen cleaving
enzymes, have come to fulﬁll novel functions in biology. Here we1 416 946 2984.
kha).
ll rights reserved.describe the growing body of evidence thatmetalloproteinases impact
not only ECM remodeling but also cellular interactions in the matrix-
rich skeleton. Metalloproteinases are named for their dependence on
a zinc ion at the catalytic site, which is coordinated by a water
molecule and 3 conserved histidine residues [1]. Matrix metallopro-
teinases (MMPs) are soluble proteases, with the exception of the 6
membrane type MMPs (MT-MMPs), and are primarily involved in
cleaving speciﬁc ECM substrates along with cytokines and growth
factors. Cell surface-bound proteinases termed ADAMs (A disintegrin
and metalloproteinase[s]) have the capacity to shed growth factors,
cytokines and their receptors from cell membranes. ADAMs with
thrombospondin domains (ADAMTSs) are also soluble proteases
principally involved in collagen and proteoglycan processing. These
enzymes are regulated transcriptionally, through the activation of
their zymogen forms and by their endogenous inhibitors, called
tissue inhibitors ofmetalloproteinases (TIMPs) [2]. Fig.1 illustrates the
metalloproteinases and TIMPs localized to speciﬁc skeletal cell types
by in situ hybridization. Evidence of metalloproteinase expression by
primary bone cell cultures is not included. Of the MMPs expressed in
bone,MMP2 andMMP13 have been linked to inherited human skeletal
disorders. MMP2 mutations were identiﬁed in several multicentric
osteolysis syndromes, while the Missouri variant of spondyloepimeta-
physeal dysplasia (SEMDMO) is caused by a missense mutation in
MMP13 (reviewed by Fanjul-Fernándes et al. in this issue). Genetic
mouse models have informed the study of these diseases and,
conversely, the recognition of these syndromes has led to more
speciﬁc analysis of the models.
This review focuses on data derived from the study of mice lacking
metalloproteinases, either singly or in pairs, and of knock-in mice
Fig. 1. Expression of metalloproteinases and their inhibitors in murine bone. A typical long bone is depicted with enlargements showing speciﬁc cell types. MT1-MMP is widely
expressed in articular cartilage [116], the periosteum [7,69,116], osteocytes [69], osteoblasts [117] and osteoclasts [116,118]. MMP13 is speciﬁcally expressed in hypertrophic
chondrocytes [23] as well as in the periosteum [69], osteocytes [69] and osteoblasts [23,35]. MMP2 is similarly found in the periosteum [116], osteocytes [33] and osteoblasts [117].
MMP9 is uniquely expressed by osteoclasts [16,22,119,120]. MT3-MMP is detected in the periosteum and in resting and proliferating chondrocytes [7]. ADAM-TS1 is expressed in
articular cartilage and by hypertrophic chondrocytes [95]. Of the TIMPs, TIMP2 is expressed in articular cartilage [116] and osteoblasts [117] while TIMP3 is expressed in hypertrophic
chondrocytes [121]. Only in situ hybridization studies which indicate the cell types responsible for metalloproteinase or TIMP expression are included.
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metalloproteinase subsets. Most single metalloproteinase-deﬁcient
mice are born at the expected Mendelian ratios and have normal life
spans, although certain ADAMs and MMPs are indispensable for
proper embryonic development and postnatal survival. Adam10 null
mice die at E9.5 [3], while mice with catalytically inactive Adam17/
Tace (TNF-alpha converting enzyme) die between E17.5 and one day
after birth [4]. Of the single MMP deﬁcient mice generated to date,
only Mt1-Mmp nulls display reduced viability by weaning age [5,6].
The combined loss of Mt1-Mmp and Mt3-Mmp leads to lethality one
day after birth due to clefting of the palate [7], while that ofMt1-Mmp
and Mmp2 results in a failure to initiate breathing and death within
minutes of birth [8]. We integrate the information acquired through
the study of the skeletons of these and other mouse models to
highlight the commonalities and differences between metallo-
proteinase function in skeletal development, the regulation of bone
remodeling and the progression of joint disease.
2. Metalloproteinases in skeletal development
Formation of the skeleton has long been known to require the
progression of two major ossiﬁcation processes. Endochondral
ossiﬁcation leads to the development of most bones in the body,
while intramembranous ossiﬁcation is essential for the establishment
of ﬂat bones. More recently, through the study of MMP deﬁcient mice,
a localized remodeling process was revealed to be important at
speciﬁc sites throughout the skeleton. An excellent review by Krane
and Inada comprehensively describes the skeletal phenotypes inMMP
deﬁcient mice [9]. Here, we present these developmental changes in
the context of steps in the ossiﬁcation process and additionally include
relevant ADAM and ADAMTS skeletal phenotypes.2.1. Metalloproteinases in endochondral bone development
2.1.1. Mesenchymal cell condensation
The ﬁrst step in the development of themammalian skeleton is the
condensation of mesenchymal cells derived from the somatic layer of
lateral platemesoderm [10]. The physical compaction of mesenchymal
cells has two phases, which involve changes in the ECM and the
establishment of cell–cell contact. Increased hyaluronidase activity
degrades hyaluronan while the ﬁbronectin content of the matrix
increases. Subsequently, cell–cell interactions are created, speciﬁcally
through neural-cadherin (N-cadherin) and neural cell adhesion
molecule (N-CAM) (reviewed in [11]). The remaining undifferentiated
mesenchymal cells surround the cartilage core and form the
perichondrium which later gives rise to osteoblasts (Fig. 2A). The
role of metalloproteinases in the condensation and differentiation of
mesenchymal cells to cartilage has not been well studied. N-cadherin
is shed by the sequential activities of ADAM10 and the gamma-
secretase complex in neuronal cells [12,13] and it has been recently
demonstrated that N-cadherin can be shed by MMP9 and MMP12 in
vascular smooth muscle cells [14]. N-CAM, a less well-established
metalloproteinase target, can be cleaved in vitro by Xenopus MMP28
[15], but the efﬁciency of the human and murine MMP28 orthologs in
N-CAM cleavage has not been described. Thus far, evidence frommouse
models suggests that individualmetalloproteinasesdonotplayessential
roles in mesenchymal condensation as the metalloproteinase-deﬁcient
mice generated to date have proper skeletal templates.
2.1.2. Chondrocyte proliferation
Once mesenchymal cells compact, chondrocyte differentiation is
initiated. The former mesenchymal cells acquire the typical rounded
appearance of chondrocytes and begin synthesizing a matrix high in
Fig. 2. Endochondral bone development is impacted by metalloproteinase loss in genetic models. (A) Endochondral ossiﬁcation begins during embryogenesis when mesenchymal
tissue condenses. (B) Mesenchymal cells differentiate into chondrocytes, and the most centrally located of these begin to proliferate. Remaining mesenchymal cells surrounding the
cartilage core form the perichondrium. (C) Chondrocytes withdraw from the cell cycle, enter the prehypertrophic stage and progress to hypertrophy, enlarging and mineralizing the
surrounding matrix. Hypertrophic chondrocytes induce cells within the perichondrium to differentiate into osteoblasts and form a bone collar. (D) The primary ossiﬁcation centre is
formed when the scaffold of mineralized cartilage is invaded by blood vessels carrying hematopoietic cells that populate the marrow cavity and give rise to osteoblasts and
osteoclasts. (E) Osteoclasts/chondroclasts degrade the transverse bridges that previously surrounded the hypertrophic chondrocytes, leaving behind spicules of cartilage that form
the basis of the trabecular bone spicules. Osteoblasts deposit their own matrix on these calciﬁed cartilage templates. Concurrently, chondrocytes in the bone epiphyses have been
maturing and are invaded by blood vessels. (F) The secondary ossiﬁcation centres form leaving articular cartilage to cushion joint surfaces and growth plate cartilage separating the
diaphysis of the bone from the epiphyses. (G) The phenotypes observed in metalloproteinase null mice, with arrows indicating the stage of development impacted. (;) = double
deﬁcient mice, (/) = conditional knockout.
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form organized columns of cells that result in the longitudinal
extension of the cartilage template (Fig. 2B). Disorganized columns
of chondrocytes are observed in the developing bones of Mmp13−/−
and Mt1-Mmp−/− mice [5,6,16]. In both cases these changes are notdue to alterations in the expression of the essential cartilage
signaling molecules, Indian hedgehog (Ihh) and its receptor patched
(Ptc), or the PTH/PTHrP (parathyroid hormone/parathyroid
hormone-related peptide) receptor (PPR) [5,16]. Additionally, in
Mt1-Mmp−/− mice, decreased chondrocyte proliferation is observed
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proliferating chondrocytes in Mt3-Mmp−/− mice is also character-
ized by decreased proliferation [7]. However, the combined loss of
Mt1-Mmp and Mt3-Mmp does not further decrease proliferation
when compared to the levels in Mt1-Mmp−/− mice, indicating a
common function of MT1-MMP and MT3-MMP in the maintenance
of proliferating chondrocytes [7]. Recently, using a Sox9-Cre
promoter, Adam17 was conditionally deleted in cells of the osteoblast
and chondrocyte lineages (Tace/Sox9 mice) [17]. This loss of TACE
activity caused a shortening of the zone of proliferating chondrocytes
and a decrease in the overall level of chondrocyte proliferation [17].
Primary knockout and wild type chondrocyte cultures proliferated at
the same rate, suggesting that cell-extrinsic mechanisms are
responsible for the in vivo phenotype [17].
2.1.3. Chondrocyte hypertrophy
The transition of proliferating chondrocytes to the prehypertrophic
stage is marked by a cessation of proliferation and a shift in the
balance of collagen production from type II to type X [18]. Prehyper-
trophic chondrocytes secrete Ihh, which increases the proliferation of
the less mature chondrocyte population and, by upregulating
perichondrial PTHrP secretion, delays the progression of prehyper-
trophic cells to hypertrophy [19]. When chondrocytes enter the
hypertrophic stage they expand in size 5–10 fold, secrete type X
collagen, deposit vascular endothelial growth factor (VEGF) into the
matrix [19,20], as well as produce alkaline phosphatase and calcify
their ECM [21]. Terminally hypertrophic chondrocytes additionally
express Mmp13 prior to undergoing apoptosis, and leave behind
empty lacunae surrounded by a calciﬁed matrix that is subsequently
remodeled into bone. During this process, Ihh secreted by prehyper-
trophic chondrocytes also induces mesenchymal cells within the
perichondrium to differentiate into osteoblasts and form a collar of
bone around the cartilage template in a PTHrP dependent manner [19]
(Fig. 2C). Given that the expression of Ihh has not been found to be
altered in MMP deﬁcient bones by in situ hybridization, it is not
surprising that no defects are reported in bone collar formation in
these mice.
Metalloproteinase loss affects the hypertrophic stage of cartilage
development more strongly than the proliferative stage. Expansion of
the hypertrophic zone has been noted in several single and double
metalloproteinase knockout mice with varied severity. Prenatally, the
hypertrophic zones in the long bones of E16.5Mt1-Mmp−/− embryos
are expanded 3–4 times compared to those in wild type embryos but
the severity of this phenotype decreases with age [5]. Mice doubly
deﬁcient for Mt1-Mmp and Mt3-Mmp, similarly have an expanded
hypertrophic zone at birth [7]. At this stage, the hypertrophic zone in
Mmp9−/− mice is approximately twice as long as in wild type mice
and increases 6–8 times by 3 weeks of age [22]. While the
hypertrophic chondrocytes in these mice are morphologically normal
and able to calcify the matrix, their death by apoptosis is delayed [22].
Increased hypertrophic zones are also noted in a variety of bones in
Mmp13−/− mice, but with different severities and timelines. The
population of most terminally differentiated hypertrophic chondro-
cytes, which normally express Mmp13 and osteopontin, is speciﬁcally
expanded [16,23]. Chondrocyte-speciﬁc deletion of Mmp13 through
the use of Cre recombinase expressed under the type II collagen
promoter in chondrocytes did not rescue this phenotype, while
osteoblast-speciﬁc deletion using the type I collagen promoter
resulted in a normal growth plate, demonstrating that chondrocyte
produced MMP13 is essential for the proper remodeling of hyper-
trophic cartilage early in development [23]. However, such increases
are transient as the hypertrophic zones of Mmp9−/− and Mmp13−/−
mice are comparable to those of wild type mice by 8 and 12 weeks of
age, respectively [22,23]. Similarly, the metatarsals of Tace/Sox9 mice
display a transient expansion of the hypertrophic zone at 2–3weeks of
age that resolves by 8 weeks of age [17]. It should be noted that inanother model ofMmp13−/−mice a mild increase in the growth plate
width persists at least until 16 weeks of age [16]. Together, these
studies indicate that in the absence of a critical MMP, alternate means
of cartilage turnover are employed. The compensatory roles of MMP9
and MMP13 in hypertrophic cartilage remodeling are suggested in
double Mmp9−/−Mmp13−/− knockout mice which have overpopu-
lated, dramatically expanded zones of hypertrophic cartilage with
disrupted architecture at 5 weeks of age. Notably, even this phenotype
resolves by 5 months of age [23].
Growth plate defects do not occur in mice deﬁcient in Adamts1
[24], Adamts4 [25] or Adamts5 [26]. Consistent with this, transgenic
mice expressing mutated aggrecan that cannot be cleaved by either
MMPs [27] or ADAMTSs [28] fail to show growth plate or overall bone
defects. Of the ADAMTSs, ADAMTS4 is the primary aggrecanase
expressed in the growth plate. The lack of aggrecan accumulation in
Adamts4−/−, Adamts5−/− or Adamts4−/−Adamts5−/− mice, and the
absence of detectable compensatory aggrecan cleavage probed
through neo-epitope antibodies suggests that growth plate aggrecan
is cleared by mechanisms other than metalloproteinase-mediated
activity [25,29].
2.1.4. Vascular invasion and ossiﬁcation centre formation
The progression of endochondral ossiﬁcation requires that bone
building cells, osteoblasts, and bone degrading cells, osteoclasts, have
access to the cartilage. This occurs via blood vessel invasion into the
hypertrophic zone (Fig. 2D), which is initiated by hypertrophic
chondrocyte secretion of VEGF, and delivers osteoblasts and hemato-
poietic cells, including osteoclast precursors. The degradation of the
cartilage matrix is suggested to occur speciﬁcally through the actions
of cells called chondroclasts [22], although the precise nature of these
cells and their relation to osteoclasts is unclear. Regardless, once
differentiated, osteoclasts/chondroclasts begin degrading the calciﬁed
cartilage matrix, carving out a space termed the primary ossiﬁcation
centre in the middle of the bone. At the same time, osteoblasts begin
laying down a bone matrix on the remaining spicules of cartilage
matrix (Fig. 2E). With time and as the primary ossiﬁcation centre
expands, these spicules are completely replaced with bone matrix.
Soon after birth, this process is repeated in the epiphyses (ends) of the
bone. Here, vascular invasion through uncalciﬁed cartilage creates the
secondary ossiﬁcation centres leaving articular cartilage at the joint
surfaces and growth plate cartilage separating the primary and
secondary ossiﬁcation centres (Fig. 2F).
Proper remodeling of the ossiﬁcation centres is impacted by the
loss of individual or pairs of MMPs. Mmp9−/− mice display markedly
delayed enlargement of the primary ossiﬁcation centre [22]. The
abnormally expanded zone of hypertrophic cartilage is eventually
remodeled ectopically following aberrant chondrocyte apoptosis [22].
Ex vivo growth plate cultures allowed the study of blood vessel
formation and indicated that reduced angiogenesis delays growth
plate remodeling in Mmp9−/− mice [22]. Impaired blood vessel
invasion is also noted in Mt1-Mmp−/− mice where the primary
ossiﬁcation centre forms appropriately, but the creation of the
secondary ossiﬁcation centres is delayed and occurs in an unusual
manner [5]; once the cartilage adjacent to the bone calciﬁes, the
ossiﬁcation front follows osteoclast migration from the periphery
towards the middle, as opposed to progressing outwards from the
middle following vascular invasion [5,6]. The effect of Mmp13 loss on
the formation of the primary ossiﬁcation centre is less clear. One study
reported no difference in the initiation of the primary centre nor in the
distribution of angiogenic markers [23] while another group reported
a delay in centre formation from E15.5 to E17.5 [16]. However, both
studies are in agreement in observing a lack of staining for collagen
neo-epitopes at the last transverse septae (horizontal bridge of matrix
closest to the ossiﬁcation front) of the growth plates of Mmp13−/−
mice, suggesting that MMP13 is the primary collagenase at this site
[16,23]. The completion of the primary ossiﬁcation centre formation is
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knockouts, and these double knockouts also exhibit delayed develop-
ment of the secondary ossiﬁcation centres [23]. Further, the neo-
epitope generated by MMP cleavage of aggrecan is absent at their
ossiﬁcation front, although it is seen in Mmp9−/−, Mmp13−/− and
wild type mice indicating the involvement of both of these MMPs in
the cleavage of aggrecan [23]. Recently, antibodies raised against the
neo-epitopes exposed when MMP2, 9 and 13 lose their pro-domains
were used to localize active MMPs during the invasion of vascular
canals that create the secondary ossiﬁcation centre [30]. In line with
the genetic data described above, Lee et al. found that MT1-MMP is
cell-bound at the invasion front, while active MMP13 and MMP9, but
not MMP2, are detected in the ECM and are associated with type II
collagen degradation [30]. Analysis of another double knockout
combination, Mt1-Mmp−/−Mt3-Mmp−/−, revealed a prominent
phenotype where islands of intact hypertrophic cartilage remain
within the primary ossiﬁcation centre of long bones in newborn mice
[7]. This demonstrates a role of these membrane anchored metallo-
proteinases in efﬁcient cartilage remodeling. Further analysis of
primary and secondary ossiﬁcation centre formation was prevented
by the early death of these double mutants. Lastly, a brief report noted
a delay in osteoclast invasion into the hypertrophic cartilage of the
metatarsals of E18.5 Tacezn/znmice where TACE is catalytically inactive
due to the deletion of the zinc binding domain [31]. However, the
progression of ossiﬁcation centre formation was not described, nor
was the distribution of VEGF or endothelial cells. These features have
not yet been described in Tace/Sox9 conditional knockout mice [17].
Overall, these murine studies show that MMP activity is important,
but individually not essential, for the ultimate formation of the bone
marrow cavity.
2.2. Intramembranous ossiﬁcation
While themajority of the skeleton develops through endochondral
ossiﬁcation, the ﬂat bones of the skull, the mandible and part of the
clavicles arise by intramembranous ossiﬁcation. This process begins
with the condensation of mesenchymal cells derived from the neural
crest and paraxial mesoderm rather than from the lateral plate
mesoderm as in endochondral ossiﬁcation [10]. During intramem-
branous ossiﬁcation mesenchymal cells differentiate into osteoblasts,
not chondrocytes, and directly calcify the matrix.
Mmp2 knockoutmicewere originally reported to develop normally
with only a slight growth delay [32]. However, identiﬁcation of the
human nodulosis, arthropathy, osteolysis (NOA) familial syndrome
caused by an MMP2 mutation prompted closer inspection of these
mice and several deformities were subsequently reported. Snout, jaw
and overall skull length are decreased, the cranial vault is dome-
shaped and the sutures are sclerotic in Mmp2−/− mice [33,34].
Col1a1r/r knock-in mice, which harbour an engineered mutation in
Col1a1 that results in type I collagen which is resistant to collagenase
activity, also exhibit changes in the skull starting at 6 weeks and
progressing with age [35]. Combining these two mutant strains
(Mmp2−/−Col1a1r/r) causes severe runting and a decreased lifespan,
with more pronounced skull defects than those seen in either mutant
alone. The calvarial bones are not fully formed even at 5months of age,
sclerotic membranes persist instead of bone in the calvaria, and
sutures that do form are thin and porous in these double mutant mice
[36]. Similarly,Mt1-Mmp−/−mice have prominent sutures, shortened
mandibular and maxillary bones, dome-shaped cranial vaults, and
have incomplete suture closure between the parietal and interparietal
bones [5,6]. Severe membranous bone deformities arise in Mt1-Mmp
and Mt3-Mmp double knockout mice. At birth these mice display
shortened, domed skulls, poorly formed bones, decreased bone
mineralization and, fatally, cleft palates [7]. The contributions of
osteocyte activity to the skull phenotypes in Col1a1r/r, Mmp2−/− and
Mt1-Mmp−/− mice will be described later (Section 3.3).2.3. Non-endochondral cartilage remodeling
A distinct process in bone development that involves the remodel-
ing of speciﬁc cartilage elements was identiﬁed through the observa-
tion of “ghost cartilage” remnants in the skulls of Mt1-Mmp deﬁcient
mice, and termed metamorphic remodeling. This observation
prompted Holmbeck et al. to identify focal sites other than the calvaria
where this process occurs: i) Merckel's cartilage, the cartilage
precursor for the mandible, malleus of the inner ear and spheno-
mandibular ligament, ii) the insertion sites of ligaments into cartilage
and bone, and iii) the groove of Ranvier in long bones [6,37]. While the
remodeling of cartilage during endochondral development is depen-
dent on the actions of osteoblasts and osteoclasts, it has been proposed
that metamorphic remodeling is carried out by chondrocytes them-
selves. Mt1-Mmp expression by non-hypertrophic chondrocytes leads
to degradation of the unmineralized cartilage matrix and chondrocyte
apoptosis [37]. Such non-endochondral cartilage remodeling is limited
to speciﬁc tissues and is a previously unappreciated, yet essential part
of skeletal development at these sites.
3. Metalloproteinases facilitate bone cell interactions during
skeletal remodeling
Bone remodeling occurs throughout adult life and is essential
for maintaining bone health and circulating calcium levels
(reviewed in [38]). An imbalance between resorption and deposi-
tion underlies diseases where bone density is altered including
osteopetrosis, and more commonly, osteopenia and osteoporosis.
Several metalloproteinase-deﬁcient mice have abnormal bone
remodeling as summarized in Table 1. Given the established role
of metalloproteinases in matrix degradation, one might expect that
they contribute directly to bone resorption. However, metallo-
proteinases function at physiological pH and the acidic environment
of the osteoclast resorptive pit is not conducive to their activity.
Rather, the cathepsins, largely belonging to the cysteine protease
family, are responsible for osteoclastic bone resorption, with
cathepsin K being the primary effector [39–41].
We describe below the varied roles of metalloproteinases in bone
remodeling, which include i) regulating the bioavailability of critical
factors, ii) operating as effectors upon hormonal stimulation, and iii)
causing structural changes to enable the development of the osteocyte
canalicular network. This physical network allows osteocyte processes
to form gap junctions that make possible the transfer of secreted
proteins between other osteocytes as well as osteoblasts [42]. In each
case metalloproteinase activity is important for regulating or estab-
lishing communication between bone cells — osteoblasts, osteoclasts
and osteocytes. When these means of communication are perturbed
by the absence of a speciﬁc metalloproteinase activity, the balance of
bone remodeling is altered and changes in the bone structure result.
3.1. Metalloproteinases regulate osteoclast activation via the
RANK/RANKL/OPG axis
As mentioned, both bone resorption by osteoclasts and bone
deposition by osteoblasts are necessary for appropriate bone growth
and remodeling. Until a decade ago, the factors regulating
osteoclastogenesis were unknown, although it was hypothesized
that stromal cells and osteoblasts played a role in osteoclast
differentiation. The discovery of the secreted receptor osteoprote-
grin (OPG) led to the identiﬁcation of its ligand, originally named
OPGL, which was found to be identical to TNF-related activation
induced cytokine (TRANCE) expressed on activated T-cells, and is
most commonly referred to as receptor activator of NFκB ligand
(RANKL) due to its association with the receptor RANK (reviewed in
[43]). The importance of the OPG/RANK/RANKL triad in bone
biology was demonstrated in mice deﬁcient in these molecules.
Table 1
Long bone remodeling in genetic mouse models with impaired metalloproteinase activity.
Osteoblasts Osteoclasts Osteocytes Trabecular bone Cortical bone
Mmp2−/− [33,34] Transiently decreased
numbers (4d), decreased
ability to differentiate in vitro
Transiently decreased
numbers (4d), decreased
ability to differentiate in vitro
Mildly disrupted canalicular
network and no difference in
viability (5w onwards)
Decreased mineralization
(5w onwards), transiently
decreased volume (4d)
Decreased mineralization
(5w onwards), ragged
appearance (4d)
Mmp9−/− [22] Transiently decreased (3w),
then increased (4w), then
normal (8w)
No difference
Mmp13−/− [23] No difference in proliferation No difference in number,
localization
Increased (3w-6m),
resolved by 1y
No difference
Mt1-Mmp−/− [6,69] Decreased activity and
viability (40d onwards)
Increased activity and
numbers (40d onwards)
Severely disrupted canalicular
network but no change in
viability (20d onwards)
Decreased (40d onwards) Decreased (40d onwards)
Tace−/−/Sox9 [17] Increased activity (8w) Increased numbers,
activity (8w)
Decreased (8w onwards) Decreased (8w onwards)
Col1a1r/r [33,35,61] Decreased viability,
activity (4w)
Increased numbers, decreased
activity (4w)
Severely disrupted canalicular
network and fewer viable
osteocytes (3w onwards)
Increased (4w onwards) No change (4w),
increased (10m)
d = day; w = week; m = month; y = year.
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mature osteoclasts, whereas mice lacking the decoy receptor OPG
have excessive osteoclast activity and develop osteoporosis [44–46].
Speciﬁcally, RANKL expressed by both stromal cells and mature
osteoblasts interacts with its receptor RANK on osteoclast precursors
(Fig. 3A), triggering multiple signal transduction pathways that
drive osteoclast maturation and activation [47].
Soon after the discovery of the OPG/RANK/RANKL triad, it was
shown that RANKL can be shed from the cell surface and that normally
this shedding downregulates osteoclast activation [48,49]. Several
metalloproteinases have been investigated as putative RANKL shed-
dases (reviewed in [50]). While TACE and ADAM19 are able to cleave
RANKL peptides in vitro, TACE is unable to cleave full length RANKL
[51] and ADAM19 only does so when over-expressed [52]. ADAM19
does not generate the same cleavage products as detected in primary
osteoblast cultures [53]. On the other hand, MT1-MMP shedding of
RANKL has been observed in primary osteoblast cultures and ADAM10
also produces cleavage products identical to those generated in
primary osteoblasts. Thus these two proteases are likely the physio-
logically relevant RANKL sheddases (Fig. 3A) [53]. The in vivo effect of
ADAM10-mediated RANKL shedding is unknown as Adam10 null mice
die at E9.5 before the formation of the skeleton [3], and to date no
skeletal-speciﬁc deletion of Adam10 has been reported. The excessive
osteoclast activity and early onset osteopenia inMt1-Mmp−/−mice [6]
could possibly arise from an increased bioavailability of cell-anchored
RANKL. It should be noted that changes in osteoblast characteristics
also likely contribute to osteopenia in Mt1-Mmp null mice; osteoblast
activity and proliferation are decreased, osteoblasts lining the
periosteal bone surface are displaced into the ﬁbrotic periosteum
and they have a decreased capacity to cleave collagen substrates [6].
The molecular mechanism(s) by which MT1-MMP loss causes these
changes in osteoblasts has yet to be elucidated.
The activity of soluble RANKL and the metalloproteinases
responsible for its shedding appear to be altered in pathological
settings. While the shedding of RANKL at physiological levels
downregulates osteoclast activation, high levels of soluble RANKL,
either globally or focally, are able to efﬁciently activate osteoclasts.
Overexpression of a soluble RANKL construct in mice caused
osteoporosis [54]. In a model of prostate cancer metastasis to
bone, MMP7 sheds RANKL leading to osteoclast activation and
osteolysis [55] (Fig. 3A). Mmp7−/− mice have been described as
phenotypically normal, although a detailed examination of their
skeletons has not been reported [56]. Overall, metalloproteinases are
important in regulating physiological and pathological osteoclasto-
genesis, as the ability to shed RANKL provides stromal cells and
osteoblasts with an additional level of control in mediating osteoclast
maturation and activation.3.2. Osteoblastic MMP13 mediates PTH catabolic signals
Parathyroid hormone (PTH) is produced by the parathyroid glands
to maintain calcium homeostasis. Intermittent exposure of bone to
low levels of PTH results in an overall anabolic effect and is a current
therapy for osteoporotic patients, but high PTH levels promote
catabolic activity, releasing calcium into the blood [57]. Although
osteoclasts are the ultimate target of PTH stimulation, it is osteoblasts
that normally express its receptor PPR and mediate PTH signals
(reviewed in [58]). PPR activation in osteoblasts leads to protein
kinase A signaling which triggers changes in gene expression,
including downregulation of type I collagen, osteonectin and alkaline
phosphatase, and upregulation of RANKL and MMP13 (Fig. 3B)
(reviewed in [59]). MMP13 is the only reported MMP to be induced
in response to catabolic PTH stimulation.
Striking evidence of the importance ofMMPactivity in the catabolic
response to PTH is observed in Col1a1r/r mice. Typically, repeated
supra-calvarial injection of PTH leads to increased bone resorption as
seen by enlarged marrow spaces and prominent osteoclasts in wild
typemice. In Col1a1r/rmutants, however, few osteoclasts are observed
and bone resorption is minimal even though the osteoblastic response
to PTH and MMP13 production are intact [60]. In line with this data,
whenmice expressing a constitutively activated PPR in osteoblasts are
crossed with Col1a1r/r mice, osteoclast activity is diminished [61]. The
effect of exogenous PTH has not been determined inMmp13−/−mice,
although this MMP is critical in bone remodeling as Mmp13−/− mice
uniquely exhibit osteopetrotic changes in trabecular bone; other MMP
knockout mice show either no change or osteopenia as outlined in
Table 1 [16,23]. Elegant genetic experiments by Stickens et al. show
that this increase in trabecular bone is due to the speciﬁc loss ofMmp13
in osteoblast and not in chondrocyte populations [23]. These studies
suggest that the inability of osteoblasts to transmit PTH signals to
osteoclasts may contribute to the osteopetrosis inMmp13−/−mice.
As an established target of PTH-mediated gene regulation, MMP13
is considered to be the principal metalloproteinase involved in
generating signals that recruit or activate osteoclasts, with the
postulated mechanisms illustrated in Fig. 3B. Early in vitro experi-
ments showed that interstitial collagenase can prime bone for
osteoclast resorption by clearing surface collagen and exposing the
underlying mineralized bone [62,63]. Additionally, collagenase
digested collagen fragments can stimulate osteoclast activity [62,63].
Furthermore, it is possible that collagen cleavage reveals cryptic sites
important for osteoclast survival [60]. Survival signaling is likely
mediated through interaction with αvβ3 integrin, which is highly
expressed by osteoclasts and involved in bone resorption [64–66],
although, direct evidence to support the role of cryptic peptides in
osteoclast survival is lacking.
Fig. 3. Metalloproteinases enable communication between bone cells. (A) RANKL shedding from stromal cells or osteoblasts at physiological levels decreases the amount of
biologically active RANKL and downregulates osteoclastogenesis. (B) In pathological settings, excessive RANKL shedding creates a local pool of soluble RANKL that activates osteoclast
precursors and upregulates osteoclastogenesis. (C) PTH stimulation of osteoblasts leads to the production of the collagenolytic MMP13. The cleavage of collagen type I by MMP13
contributes through unknown mechanisms to osteoclast activation, potentially by pre-clearing surface collagen and facilitating osteoclast attachment and/or by generating cryptic
collagen fragments that interact with osteoclast αvβ3 integrin receptors to promote osteoclast survival. (D) MMP2, MMP13 and MT1-MMP create and maintain the osteocyte
canalicular network allowing communication between osteocytes as well as osteoblasts at the bone surface. The osteocyte-secreted protein, sclerostin, downregulates osteoblast
activity at the bone surface. MMP2 and MMP13 activity is also important for osteocyte survival, through unknown mechanisms. (E) In the absence of MMP2, MMP13 or MT1-MMP
the canalicular network is disrupted and calvarial bone thickens, likely due to the absence of sclerostin inhibitory activity on osteoblasts. Empty lacunae and osteocytes undergoing
apoptosis are common in MMP2 and MMP13 deﬁcient calvaria.
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cell–cell communication
Osteocytes are cells of osteoblastic origin that reside in lacunae
within the bone matrix. By sending cellular processes through an
extensive network of canaliculi they establish gap junctions and
maintain physical connections with osteoblasts at the surface and
other osteocytes [42]. Osteocytes make up 90–95% of the total cells in
adult bone and are believed to be the primary, if not sole, sensors of
mechanical strain on the bone by detecting shear stress caused by
ﬂuid movement within the canalicular network (reviewed in [67]).
The ability of osteocytes to sense decreased bone loading and effect
changes in osteoblast and osteoclast activity were demonstrated invivo through the speciﬁc ablation of approximately 70–80% of the
osteocyte population in adult mouse bones [68]. These mice were
resistant to unloading-induced bone loss following tail suspension
[68], and highlight the importance of an intact osteocyte network for
communicating signals to cells present at the bone surface.
The presence of a proper canalicular network is integral to
osteocyte communication and metalloproteinase activity is necessary
to establish and maintain this network. The ﬁrst evidence of this was
shown by Zhao et al. in 2000. Col1a1r/r mice have an increased
number of empty lacunae, as well as increased apoptosis of the
remaining osteocytes at 1 month of age, that persists at 12 months of
age in both the calvaria and long bones [35]. This ﬁnding is associated
with increased bone deposition at both sites in the agedmice [35]. The
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of thickened bones containing a higher number of empty osteocyte
lacunae and increased osteocyte apoptosis [33]. However, unlike in
the Col1a1r/r mice, the long bones ofMmp2−/−mice do not show the
same defects and have deﬁcient mineralization [33,34]. When
measured, the canalicular network was moderately decreased in
Mmp2−/− long bones but more severely affected in Mmp2−/−
calvaria, while both calvaria and long bones in Col1a1r/r mice showed
a severe disruption [33]. A compromised network of osteocyte
processes is also noted in the long bones of Mt1-Mmp−/− mice
starting as early as 20 days of age, however osteocyte viability is not
affected in these mice [69]. The importance of collagen cleavage for
osteocyte viability is not well understood. MT1-MMP is an important
component of the triad necessary for MMP2 activation [70–72] and
MMP2 activation is severely compromised in Mt1-Mmp−/− mice [5].
It is possible that theminimal residual MMP2 activity inMt1-Mmp−/−
mice is sufﬁcient to protect osteocytes against the apoptosis observed
in Mmp2−/− bones. The lack of osteocyte apoptosis in Mt1-Mmp−/−
mice also suggests that the absence of a well-developed canalicular
network is, in itself, insufﬁcient to induce osteocyte death.
The requirement of MMP activity for carving out canalicular spaces
is not surprising. Wild type osteocytes express Mmp2, Mmp13 and
Mt1-Mmp [33,69,73] and MMP-mediated collagen cleavage products
are localized around osteocyte bodies and processes [35,69]. As
expected, these cleaved collagen fragments are not observed in
Col1a1r/r mice [35]. Strikingly, however, they are also undetectable in
Mt1-Mmp−/− mice, suggesting that the MMP13 which is produced
cannot sufﬁciently compensate for the lack of MT1-MMP activity
during the invasion of osteocyte process into the bone matrix [69]. It
remains possible that MMP13 is not efﬁciently activated in this case, as
both MT1-MMP and MMP2 are known to activate MMP13 in vitro
[74,75]. To date, the canalicular networks ofMmp13−/−mice have not
been examined. The link between osteocyte network integrity and
increased bone formation may be related to changes in the distribu-
tion of osteocyte-produced proteins. Sclerostin is secreted by
osteocytes and delivered to osteoblasts at the bone surface where it
acts as a negative regulator of osteoblast activity [76,77] (Fig. 3D).
Mice overexpressing sclerostin have decreased bone mass and
strength, while deletion of this protein causes the opposite effect
[78,79]. Osteocyte lacunae in Mmp2−/− calvaria and long bones are
characterized by a build-up of sclerostin staining [33], suggesting that
the inability of sclerostin to reach surface osteoblasts contributes to
calvarial thickening in these mice (Fig. 3E). Another osteocyte-
produced protein, dentin matrix protein-1 (DMP-1), acts as a
nucleation site for calciﬁcation, and its absence causes decreased
bone mineralization in knockout mice (reviewed in [80]). Mmp2−/−
osteocytes produce less DMP-1 protein which may contribute to the
poor mineralization of Mmp2 null long bones, but the partially intact
canalicular networkmay still deliver sufﬁcient sclerostin to osteoblasts
to prevent bone thickening [33,34]. With respect to the thickened
calvaria in Mmp2−/− mice, it is suggested that excessive osteoblast
activity due to the absence of sclerostin signaling dominates over the
impact of reduced DMP-1 on bone mineralization [33].
4. Metalloproteinase activity and joint pathologies
Having examined the roles of metalloproteinases in bone develop-
ment and remodeling, we will now describe the contributions of
metalloproteinase activity to articular cartilage integrity and the
progression of arthritic disease. Articular cartilage is organized into
four layers, namely the superﬁcial zone, intermediate zone, radial
zone and zone of calciﬁed cartilage (reviewed in [18]). Maintenance of
articular cartilage is essential for cushioning joint surfaces and
protecting the underlying bone. Also important to the function of
joints between long bones is the synovial membrane which secretes a
lubricating ﬂuid to facilitate joint motion. Loss of articular cartilageintegrity and inﬂammation of the synovial membrane are key features
of arthritic disease, which can be grouped into two conditions
differentiated by their cause and clinical features. Osteoarthritis, a
condition associated with age, gender, obesity and genetic factors, is
the most common form of arthritis and involves the loss of articular
cartilage integrity leading to degradation of the underlying bone and
localized synovial inﬂammation (reviewed in [81]). On the other
hand, joint inﬂammation is an early and sustained event in the
progression of rheumatoid arthritis, in which an inﬁltration of
inﬂammatory cells leads to the expansion of the synovium and
eventually to cartilage and bone destruction (reviewed in [82]). Here
we discuss separately the contributions of MMP, ADAMTS and ADAM
enzymes to the development of joint pathologies, again focusing on
genetic mouse models that either spontaneously develop joint
phenotypes or exhibit changes in response to the experimental
induction of arthritis.
4.1. The debated contributions of the MMP family in joint pathology
Mmp2−/−,Mt1-Mmp−/− and transgenic mice expressing activated
Mmp13 develop joint disease. As young as 12 weeks of age,Mmp2−/−
mice show early onset arthritis and joint contractures characterized
by articular cartilage destruction and erosion of the underlying bone
surface, although a normal gait is maintained in 2-year-old mice [34].
During routine handling of Mmp2−/−Col1a1r/r mice, investigators
noted a decreased range of motion at the knee, hip, shoulder, and
elbow joints but no histological examinations of the joints were
performed [36]. Joints in Mt1-Mmp−/− mice also exhibit articular
cartilage destruction, along with ankylosis, a stiffening of the joints
[6]. Other contributing factors to the ankylosis in Mt1-Mmp−/− mice
include an overgrowth of hypercellular and abnormally vascularized
synovial tissue, increased vascularity of the tendons and ligaments,
and the presence of TRAP-positive cells in articular and periarticular
soft tissues [6]. Once again, the phenotypic similarities between the
Mt1-Mmp−/− andMmp2−/−mice are notable.While joint aberrations
are not reported in Mmp13−/− mice, the induction of chondrocyte-
speciﬁc, constitutively active MMP13 in transgenic mice at weaning
age leads to the development of osteoarthritic changes [83], although
this model turns out to be complex. Here, Neuhold et al. introduce a
tetracycline-regulatable transgene intomice such that activeMMP13 is
constitutively expressed under the control of the Col2a1 promoter in
the absence of doxycycline, which is administered until weaning.
Embryonic lethality was observed even in the presence of doxycycline,
suggesting that the promoter was leaky. Interestingly, it has since been
shown that a mutant proMMP13, which folds improperly, auto-
activates in the rough endothelial reticulum, autodegrades, and
additionally activates wild type MMP13 and possibly other metallo-
proteinases [84].
With respect to arthritis models in MMP knockout mice, early work
focused on Mmp3−/− mice, which have no reported developmental
bone abnormalities. Following antigen-induced arthritis, the absence of
MMP3 activity appears sufﬁcient to prevent the detection of neo-
epitopes resulting from MMP-speciﬁc aggrecan (VDIPEN) or type II
collagen cleavage (COL2–3/4Cshort fragment) [85,86]. However, proteo-
glycan loss was found to be equivalent between knockout andwild type
mice, suggesting that MMP cleavage of aggrecan is not essential for
proteoglycan loss [85,86]. Equivalent disease progression between
Mmp3−/− andwild typemice is similarly observedwhen using collagen
to induce arthritis, but no change in VDIPEN levels was detected using
the same antibody as in the antigen-induced model [87]. Interestingly,
Mmp3−/− mice have also been subjected to osteoarthritis via surgical
induction, and here they display an accelerated progression [88]. In
another model of antigen-induced arthritis, Mmp2−/− mice develop
joint pathology characterized by increased cellular inﬁltration and
proteoglycan depletion compared with wild type controls as well as
Mmp2−/−Mmp9−/−mice, whileMmp9−/−mice display lower levels of
129A. Aiken, R. Khokha / Biochimica et Biophysica Acta 1803 (2010) 121–132both inﬁltration andproteoglycandepletion [89]. The role ofMMP12has
been tested in another species; inducing antibody-mediated arthritis in
rabbits overexpressing human MMP12 results in increased inﬂamma-
tory cell inﬁltration, proteoglycan loss and cartilage erosion [90]. In
knock-in mice named ‘Chloe’where the MMP-cleavage site of aggrecan
is mutated, the progression of surgically-induced osteoarthritis and
antibody-mediated arthritis is comparable to that in wild type mice,
indicating thatMMPs are not the primarymediators of joint destruction
[28]. Currently, the extent and nature of the contribution of MMP-
mediated aggrecan cleavage to the pathologyof humanarthritis is under
debate. As reviewed by Sandy [91], the majority of recent evidence
points to such cleavage as not being detrimental in human disease,
although it has been suggested that MMP cleavage contributes as much
as 22% of the total destructive activity in human osteoarthritis [92].
4.2. The ADAMTS family is an important mediator of arthritis
When aggrecanase 1 was cloned and identiﬁed as ADAMTS4 in
1999, it was already known that, despite aggrecan cleavage between
Asn341 and Phe342 by MMP activity, the primary aggrecan fragments
found in synovial ﬂuid from arthritic patients were cut by ‘aggreca-
nases’ between Glu373 and Ala374 [93]. That same year, aggrecanase 2
was also cloned (now referred to as ADAMTS5, aggrecanase 2 was
originally identiﬁed as ADAMTS11) [94]. Since then, models of
induced arthritis in mice deﬁcient in Adamts1, Adamts4 and Adamts5
have served well towards unraveling the in vivo importance of
individual aggrecanase activity in joint disease. Using surgical
transection of the medial meniscotibial ligament to destabilize the
joint and cause osteoarthritic changes, Glasson et al. show that
Adamts4−/−mice are not protected from aggrecan loss [25]. Similarly,
Adamts1−/− mice remain susceptible to aggrecan loss in a model of
antigen-induced arthritis [95]. It is now clearly established that
ADAMTS5 is the primary mediator of arthritic cartilage destruction, as
shown by independently generated Adamts5 knockouts subjected to
two different models of arthritis [24,26]. Notably, the protective effect
of the lack of ADAMTS5 is speciﬁc to proteoglycan destruction and
cartilage erosion, since equivalent development of synovitis, joint
space exudate, pannus-mediated erosion and bone destruction is
observed between Adamts5−/− and wild type controls [24]. The
importance of ADAMTS5 is further enforced by a recent study showing
a comparable lack of proteoglycan loss between Adamts5−/− and
Adamts4−/−Adamts5−/−mice in a model of osteoarthritis [29].
Studies using explanted human tissue however, have shown that
both ADAMTS4 and ADAMTS5 are important during the progression of
arthritis, and this may be attributable to the differential regulation of
these ADAMTS proteases in mice and humans [96].
The normal preferred cleavage sites of both ADAMTS4 and
ADAMTS5 are located in the chondroitin sulfate-2 (CS-2) domain,
not at the Glu373–Ala374 bond in the interglobular domain (IGD) of
aggrecan [97]. However, cleavage in the CS-2 region is less detrimental
to cartilage integrity and function, as only a fraction of aggrecan-
bound glycosaminoglycan chains are lost, compared to full loss
following cleavage within the IGD which is predominant in arthritic
joints [28]. This damaging cleavage is detectable in joints with
osteoarthritis and inﬂammatory arthritis (reviewed in [98]). Little et
al. highlighted the importance of the Glu373–Ala374 cleavage site using
knock-in mice called ‘Jaffa’ which carry a cleavage-preventing
mutation at this site [28]. Induction of either osteoarthritis or
inﬂammatory arthritis in thesemutants results in decreased structural
damage and aggrecan loss compared to Chloe mice harbouring
aggrecan with a mutated MMP-cleavage site as well as wild type
controls [28].
Currently, ADAMTS4 and ADAMTS5 are of major interest as
possible drug targets for arthritic patients since the current thera-
peutic regimens of non-steroidal anti-inﬂammatory drugs and
steroids alleviate symptoms but do not prevent disease progression[99]. Also of interest, therefore, are endogenous modulators of
aggrecanase activity. Like most metalloproteinases, the aggrecanases
are secreted as inactive zymogens. Recently, the proprotein convertase
PACE-4 was shown to be secreted by human osteoarthritic chondro-
cytes, activating ADAMTS4 and ADAMTS5, but PACE-4 is not produced
by healthy articular cartilage [100]. Of the TIMPs, only TIMP3 is an
efﬁcient inhibitor of ADAMTS4 and ADAMTS5 [101–103]. Decreased
proteoglycan staining is detected in the articular cartilage of aged
Timp3−/−mice 8 months and older, where staining for both the MMP
and ADAMTS cleavage-generated aggrecan neo-epitopes is increased,
with a greater increase in theMMP neo-epitope [104]. Aged Timp3−/−
joints are characterized by increased collagen cleavage products,
especially in superﬁcial zone chondrocytes [104]. In a model of
antigen-induced arthritis, Timp3−/−mice display an initial increase in
the severity of arthritic symptoms, speciﬁcally synovial inﬂammation,
but this was equivalent to the wild type arthritic score by 2 weeks
after injection; no differences in neo-epitope staining were observed
at any timepoint [105]. This immediate arthritic response is associated
with increased serum tumor necrosis factor (TNF) levels in Timp3−/−
mice 1 h following antigen administration [105].
4.3. ADAMs and joint pathologies
ADAMs primarily act as sheddases, cleaving substrates from cell
surfaces. Given that this metalloproteinase family plays a less
prominent role in modifying the ECM, the speciﬁc contribution of
different ADAMs to the development of arthritis is less well studied
than those of MMPs and ADAMTSs. Overall, the expectation is that
ADAMs, particularly TACE, contribute to the progression of rheuma-
toid arthritis by modulating the immune response [106,107]. TACE
sheds TNF from the cell surface making it locally and systemically
available [108,109] and TNF plays an important role in the
progression of rheumatoid arthritis; anti-TNF treatments used
clinically are effective at reducing disease symptoms (reviewed in
[110]). However, the absence of viable adult TACE deﬁcient mice has
made it difﬁcult to experimentally examine the contribution of TACE
to arthritis progression. In addition to TNF shedding, TACE and
ADAM10 activity also affect the bioavailability of a number of
immune-related cytokines, chemokines and receptors (reviewed in
[111]), potentially altering the overall balance of pro-inﬂammatory
and anti-inﬂammatory signals in rheumatoid arthritis. Additionally,
as reviewed by Murphy and Nagase, many cytokines and inter-
leukins, including TNF and IL-1, induce the expression of a variety of
MMPs in joint tissues [107].
It has been suggested recently that ADAM8 may play a role in the
development of rheumatoid arthritis by positively affecting osteo-
clastogenesis [112], and further study is required to determine if
ADAM8 signiﬁcantly affects the differentiation of osteoclasts in
arthritic joints in vivo. Notably, unchallenged Adam8−/− mice do not
have detectable defects in bone development or remodeling up to
10 weeks of age [113]. The effect of aging on Adam8−/− joints has not
been reported, although it has been examined in Adam15−/−mice. In
12–14-month-old Adam15 null mice, osteoarthritic changes range
from mild synovial membrane hyperplasia to cartilage proteoglycan
loss to severe erosion of the articular cartilage [114]. Notably, these
changes are only observed in aged male mice, the joints of female
Adam15−/− knockouts are comparable to wild type, indicating a sex-
speciﬁc protective effect of this protease against osteoarthritis in
males [114]. In vitro experiments suggest that this protection occurs
through an improved ability of chondrocytes to bind collagen types II
and VI through integrins and establish survival signals [114].
Consistent with this idea, α1 integrin deﬁcient mice display a similar,
age-dependent increase in osteoarthritic changes [115]. Overall, much
work remains to be carried out before we fully understand the
function of the ADAM family of metalloproteinases in the develop-
ment of arthritic disease.
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Over the last decade, the identiﬁcation of skeletal developmental
defects, imbalances in bone remodeling and joint disease in
metalloproteinase-deﬁcient mice have cemented a role for these
proteases in bone biology and pathology. Moving forward, the major
challenge will be to tease out molecular mechanisms that explain the
observed phenotypes. Given that each metalloproteinase cleaves a
range of targets, this is not a trivial undertaking, as it is expected that
multiple biological processes may be perturbed in parallel. As also
discussed, metalloproteinases mediate communication between
speciﬁc bone cell types, and focusing on these paired interactions
may facilitate mechanistic determination.
Just as the importance of metalloproteinases in bone biology has
been increasingly appreciated in recent years, so too has the role of
these proteases in immunology and inﬂammation; genetic mouse
models deﬁcient in metalloproteinases are similarly helping to
elucidate their role in the immune system. Concurrently, the interplay
between the skeletal and immune systems has been recognized in the
relatively new ﬁeld of osteoimmunology. Metalloproteinases can shed
molecules common to skeletal and immune cells such as RANKL, are
transcriptionally regulated by inﬂammatory cytokines such as TNF,
and in turn control cytokine bioavailability. Thus, metalloproteinases
have the potential to act as key molecules in osteoimmunology.
Understanding these links will help unravel the complex biological
functions of metalloproteinases in skeletal biology and disease.
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